Molecular laboratory tests for the diagnosis of respiratory tract infection due to Staphylococcus aureus

Area of Science:

• Clinical microbiology
• Infectious diseases
• Molecular diagnostics

Background:

• Staphylococcus aureus, particularly methicillin-resistant S. aureus (MRSA), causes severe ventilator-associated pneumonia and post-influenza infections.
• Current diagnostic methods for S. aureus in respiratory secretions lack FDA clearance, delaying prompt treatment.
• Existing FDA-cleared polymerase chain reaction (PCR) tests for nasal swabs demonstrate high sensitivity and specificity.

Purpose of the Study:

• To highlight the urgent need for FDA-cleared molecular diagnostic tests for S. aureus, including MRSA, in respiratory secretions.
• To emphasize the diagnostic performance of real-time PCR for S. aureus detection in nasal swabs.

Main Methods:

• Review of current diagnostic capabilities for S. aureus and MRSA in respiratory infections.
• Analysis of performance data for real-time PCR tests used in nasal swab specimens.

Main Results:

• Real-time PCR nasal swab tests for S. aureus (MRSA) yield results in under 2 hours.
• These tests exhibit high sensitivity (95%-100%) and specificity (96%-99%), comparable to traditional cultures.
• No FDA-cleared tests currently exist for detecting S. aureus in purulent respiratory secretions.

Conclusions:

• There is a critical gap in FDA-cleared molecular diagnostics for S. aureus in respiratory tract infections.
• Expedited FDA evaluation and clearance of molecular diagnostic devices for respiratory S. aureus detection are essential.
• Development of such tests would significantly improve the prompt diagnosis and management of serious bacterial infections.